Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ruxolitinib S enantiomer (INCB18424) 是 Ruxolitinib 的 S 型对映体,是一种JAK 抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 625 | 现货 | ||
10 mg | ¥ 929 | 现货 | ||
50 mg | ¥ 2,323 | 现货 | ||
100 mg | ¥ 3,715 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 644 | 现货 |
产品描述 | Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor. |
靶点活性 | JAK2 (cell-free assay):2.8 nM, TYK2 (Cell-free assay):19 nM, JAK1 (cell-free assay):3.3 nM |
体外活性 | INCB018424(180 mg/kg,口服,每天两次)显著减少JAK2V617F驱动的小鼠模型中脾肿大和炎性细胞因子的循环水平,并优先消灭肿瘤细胞,显著延长生存期,且未产生骨髓抑制或免疫抑制.上述小鼠在第22天存活率超过90%.15 mg Ruxolitinib处理骨髓纤维化患者,每天两次,在48周时,28%患者的脾脏体积减少至少35%.Ruxolitinib组的患者整体生活质量改善,与骨髓纤维化有关的症状减轻. |
体内活性 | INCB018424在Ba/F3细胞中以剂量依赖性方式显著增加细胞凋亡。INCB018424作用于Ba/F3细胞和HEL细胞,有效且选择性抑制JAK2V617F介导的信号和增殖。INCB018424(64 nM) 导致Ba/F3细胞线粒体去极化增加一倍。INCB018424抑制正常供体和真性红细胞增多症患者提供的红系祖细胞增殖,IC50分别为407 nM 和 223 nM。INCB018424表现出对红系细胞集落形成的有效作用,IC50为67 nM。 |
激酶实验 | Recombinant proteins expressed with Sf21 cells and baculovirus vectors are purified with affinity chromatography. JAK kinase assay is done by a homogeneous time-resolved fluorescence assay with the peptide substrate (-EQEDEPEGDYFEWLE). Each enzyme reaction is carried out with Ruxolitinib or control, JAK enzyme, 500 nM peptide, adenosine triphosphate (ATP; 1 mM), and 2% dimethyl sulfoxide (DMSO) for 1 hour. IC50 is the INCB018424 concentration required for inhibition of 50% of the fluorescent signal. |
细胞实验 | Cell lines: Ba/F3 and HEL cells. Concentrations: 3 μM. Method: Cells are seeded at 2×103/well of white bottom 96-well plates,treated with INCB018424 from DMSO stocks (0.2% final DMSO concentration),and incubated for 48 hours at 37 ℃ in an atmosphere containing 5% CO2.Viability is measured by cellular ATP determination using the Cell-Titer Glo luciferase reagent or viable cell counting.Values are transformed to percent inhibition relative to vehicle control,and IC50 curves are fitted according to nonlinear regression analysis of the data using PRISM GraphPad. |
动物实验 | Animal Models: JAK2V617F-driven mouse modelFormulation & . Dosages: 5% dimethyl acetamide,0.5% methylcellulose.180 mg/kg. Administration: Oral gavage |
别名 | S-Ruxolitinib, 环丙基[4-[3-(1H-咪唑-5-基)丙氧基]苯, Ruxolitinib S enantiomer, INCB018424, INCB18424 |
分子量 | 306.36 |
分子式 | C17H18N6 |
CAS No. | 941685-37-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 57 mg/mL (186 mM)
Ethanol: 57 mg/mL (186 mM)
H2O: 5 mg/mL (16.32 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol / H2O | 1 mM | 3.2641 mL | 16.3207 mL | 32.6413 mL | 81.6033 mL |
5 mM | 0.6528 mL | 3.2641 mL | 6.5283 mL | 16.3207 mL | |
10 mM | 0.3264 mL | 1.6321 mL | 3.2641 mL | 8.1603 mL | |
DMSO / Ethanol | 20 mM | 0.1632 mL | 0.816 mL | 1.6321 mL | 4.0802 mL |
50 mM | 0.0653 mL | 0.3264 mL | 0.6528 mL | 1.6321 mL | |
100 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.816 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ruxolitinib (S enantiomer) 941685-37-6 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors Tyrosine Kinases JAK S-Ruxolitinib S-INCB18424 Ruxolitinib INCB 018424 环丙基[4-[3-(1H-咪唑-5-基)丙氧基]苯 Ruxolitinib S enantiomer INCB-18424 INCB-018424 INCB018424 Janus kinase inhibit INCB 18424 Inhibitor INCB18424 inhibitor